Soleno Therapeutics (SLNO) Income from Continuing Operations (2016 - 2017)
Historic Income from Continuing Operations for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$5.2 million.
- Soleno Therapeutics' Income from Continuing Operations fell 18361.53% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 1741.35%. This contributed to the annual value of -$175.8 million for FY2024, which is 35315.16% down from last year.
- Latest data reveals that Soleno Therapeutics reported Income from Continuing Operations of -$5.2 million as of Q4 2017, which was down 18361.53% from -$2.6 million recorded in Q3 2017.
- Over the past 5 years, Soleno Therapeutics' Income from Continuing Operations peaked at -$869278.0 during Q4 2013, and registered a low of -$5.2 million during Q4 2017.
- Moreover, its 5-year median value for Income from Continuing Operations was -$2.4 million (2015), whereas its average is -$2.6 million.
- Per our database at Business Quant, Soleno Therapeutics' Income from Continuing Operations crashed by 37925.27% in 2014 and then skyrocketed by 6781.61% in 2017.
- Quarter analysis of 5 years shows Soleno Therapeutics' Income from Continuing Operations stood at -$869278.0 in 2013, then plummeted by 379.25% to -$4.2 million in 2014, then rose by 15.85% to -$3.5 million in 2015, then soared by 47.71% to -$1.8 million in 2016, then crashed by 183.62% to -$5.2 million in 2017.
- Its Income from Continuing Operations stands at -$5.2 million for Q4 2017, versus -$2.6 million for Q3 2017 and -$3.0 million for Q2 2017.